Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Education and early detection of any type of dementia is important and may provide an opportunity for changing the course of ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Fear of a having a low blood sugar crash dissuades many people with Type 1 diabetes from getting the exercise they need, a ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

The expansion will increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease, Kisunla (donanemab-azbt). The ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...